Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI PET/CT for Evaluating Peritoneal Treatment Response
NCT06957782Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of 68Ga FAPI-46 in peritoneal metastasis (PM), sponsored by Erasmus MC. Primary endpoint: Accuracy of 68Ga-FAPI PET/CT at 18 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
peritoneal metastasis (PM)
Beyond the preview
Go deeper on NCT06957782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957782.